

THE ANTIOXIDANT ACTION OF CO₂ - ONE OF THE UNIVERSAL MECHANISMS OF CARBOXYTHERAPY

Drogovoz S. M.¹, Kalko K. O.¹, Ivantsyk L. B.¹, Shtroblyya A. L.²

Stoletov Yu. V.¹, Drogovoz K. V.¹, Ostasko V. F.¹

¹National University of Pharmacy, Kharkiv, Ukraine

²Uzhgorod national university, Uzhgorod, Ukraine

ketrin27kalko@gmail.com

Abstract

Carboxytherapy (carbon dioxide treatment) is a promising area and an alternative method of treating many diseases. Carbon dioxide (CO₂) is constantly present in the body, being the end product of cellular metabolism. It accumulates in tissues, diffuses into the blood, and is transferred to the lungs in three forms: dissolved in plasma, in bicarbonates, and as oxyhemoglobin in erythrocytes. CO₂ is totally indispensable for the normal course of biochemical, humoral, and tissue processes in the body, as it is a pacemaker of these processes.

Materials and research methods. Scientific publications in foreign and domestic journals on relevant topics over the past 5 years, Internet resources.

Research results and their discussion. Analysis of the above changes in the body under the action of CO₂ and states of biochemical markers (ADMA and d-ROM, ROS, NO, NOS) under oxidative stress indicate that CO₂ has antioxidant properties, and carboxytherapy is a pathogenetic therapy for diseases which pathogenesis includes oxidative stress. The ROS-inhibitory effect of CO₂ is universal for different cell types and, obviously, for different species of living organisms.

Conclusions. Thus, it has been established that CO₂ is a universal inhibitor of the reactive oxygen species generation by various human and animal cells. These data allow explaining the physiological and pathophysiological (medical) effects of CO₂ in the mechanism of carboxytherapy in a new way from the standpoint of the biochemical role of ROS.

Key words: *antioxidant action, carbon dioxide, carboxytherapy.*

Carboxytherapy (carbon dioxide treatment) is a promising area and an alternative method of treating many diseases [1, 2, 3, 4, 5]. Carbon dioxide (CO₂) is constantly present in the body, being the end product of cellular metabolism. It accumulates in tissues, diffuses into the blood, and is transferred to the lungs in three forms: dissolved in plasma, in bicarbonates, and as oxyhemoglobin in erythrocytes [6, 7]. The main amount of carbon dioxide - up to 90% is transferred by blood plasma in the chemically bound state as a part of bicarbonates. Transport of CO₂ by blood from the tissues to the lungs in these forms is as follows: the more CO₂ is formed, the greater amount of it is transported from the tissues to the lungs. Increased concentration of CO₂ in the body is observed at active physical loads, and also at deep controlled breath. Accumulated in the blood CO₂ is a physiological stimulator of respiration: causes the respiratory reflex, one of the main physiological effects of CO₂ in the body [8, 9]. Therefore, carbon dioxide can be considered a "signaling molecule" indicating the danger of hypoxia [7, 10]. On the content of CO₂ in the blood depends the durability of binding of oxygen to hemoglobin and O₂ ingress in tissues, as well as maintaining a stable acid-base balance (pH) in the body [10].

Thus, CO₂ is totally indispensable for the normal course of biochemical, humoral, and tissue processes in the body, as it is a pacemaker of these processes. The body needs CO₂ no less than oxygen, because, affecting the cerebral cortex, respiratory and vascular centers, it ensures the functioning of the parts of CNS, responsible for the tone of blood vessels and bronchi, heart function, metabolism, hormone secretion, electrolyte composition of blood and tissues, as well as the rate of biochemical reactions of the organism [11, 12, 13, 14, 15].

In physiological concentrations of CO₂ helps to reduce the intensity of oxidative processes: the mechanism of this action of CO₂ is

associated with the blockade of hydrogen ions. Reactive species of oxygen (ROS) include superoxide anion radical, hydroxyl radical ([•]OH), and hydrogen peroxide [16, 17]. ROS are formed in all cells that use oxygen for respiration. At physiological hypercapnia, CO₂ inhibits the formation of ROS, thus protecting the cells of the body from the destructive effects of the latter [17]. At the same time, CO₂ acts as a mediator, launching a cascade of physiological and biochemical mechanisms of regulation of all body systems (respiratory, nervous, cardiovascular, excretory, hematopoietic, immune, etc.). All these systems of vital activity of the organism play an important role in maintaining its homeostasis [12, 13, 15]. Therefore, at low blood CO₂ and bicarbonate levels in the body disrupts the cascade of natural physiological and biochemical reactions essential to maintain homeostasis. To prevent adverse manifestations of hypoxia, ischemia, and hypocapnia, it is necessary to maintain the physiological concentration of CO₂ in the blood, which is provided by carboxytherapy [18]. This therapy can act on many parts of the pathological symptom complex, which is associated with the multifunctional involvement of CO₂ in metabolic and reflex processes of systemic self-regulation of an organism, and also carboxytherapy can eliminate local problems: pain, spasm, hypoxia, ischemia, etc. [4, 7, 14, 19].

Carboxytherapy for therapeutic purposes began to be used in the first half of the twentieth century. The first article on the medical use of CO₂ was published by Brandi et al. in 1932, where it is shown that CO₂ freely passes through cell membranes and shows a pronounced vasodilating effect [7]. It was then proved that the physiological function of endogenous antioxidant defense systems of the body in combination with exogenous antioxidant properties of CO₂ are necessary to maintain a balance between endothelial relaxing factors and endothelial narrowing

factors. This balance ensures normal vascular function [20, 21]. It is now established that the antioxidant action of CO₂ is associated with the active inhibition of ROS generation. The most powerful generators of ROS are phagocytes, their generation of ROS increases especially sharply with their excitation and phagocytosis. At present, the regulatory influence of CO₂ on the generation of ROS by cells of different tissues has been established. Currently, the study of this issue is of general biological and medical interest, as CO₂ is formed constantly in all cells of the body and it is important to know its modulating influence on ROS generation.

The solution to this issue may be the results of studies conducted on 75 healthy donors, 21 patients with bronchial asthma, and 186 outbred white mice [12, 22]. It was found that CO₂ inhibits ROS generation not only in blood phagocytes and alveolar macrophages but also in tissue cells of internal organs. This inhibitory effect of CO₂ is confirmed on seven types of phagocytic cells (blood phagocytes, alveolar macrophages, tissue phagocytes: macrophages of the liver, kidneys, brain, lungs, stomach) and on six types of tissue (total parenchymal and interstitial) cells of internal organs (liver, brain kidneys, skeletal muscle) [13]. The inhibitory effect of CO₂ on the generation of ROS by blood phagocytes was also confirmed clinically. Thus, in 22 donors: it was found that CO₂ at concentrations of 5.1% and 20% inhibits the generation of ROS by phagocytes, respectively, 3.15 and 5.13 times; $p < 0.001$) [23].

In addition, under the direct influence CO₂ can inhibit the generation of ROS by mitochondria of the liver. The formation of ROS in mitochondria can occur at ischemia, inflammation, hypoxia, as well as in borderline conditions ("physiological" hypoxia of newborns, "physiological" aging), accompanied by changes in the properties of mitochondrial membranes [15, 24]. Reduction of ROS generation under the influence of 8.2% CO₂ was found not only on blood phagocytes but also on

alveolar macrophages in 21 patients with bronchial asthma. In bronchial asthma, carboxytherapy is more effective in those patients whose phagocytes have retained a high sensitivity to the inhibitory effect of CO₂ on ROS generation [16]. Given the analysis of these data, it can be assumed that the beneficial effect of CO₂ in bronchial asthma is associated with the inhibitory effect of CO₂ on ROS generation [12, 16]. Pre-inhalation by animals (42 mice) for 50 min of a gas mixture containing 8.2% CO₂ reduced the formation of ROS in the cells of the tissues of internal organs (liver, brain, lungs, myocardium, gastric pylorus, and skeletal muscle) 2.2-4.1 times.

Therefore, the ROS-inhibitory effect of CO₂ is universal for different cell types and, obviously, for different species of living organisms.

Another interesting feature, in terms of the antioxidant action of carboxytherapy, is that in the body CO₂ interacts with both active forms of O₂ and with active forms of nitrogen: in the presence of NO superoxide, peroxyxynitrite is formed, which reacts with CO₂ with the formation of nitrosoperoxyxynitrite [25]. This compound is converted to nitrocarbonate, which is prone to further reactions. Thus, in the aquatic environment, the most probable reaction involving CO₂ is the hydrolysis of nitrocarbonate to form carbonate and nitrate [17, 25].

Thus, the antioxidant effect of CO₂ is also associated with the peroxyxynitrite conversion reaction resulting in the conversion of nitration reactions and oxidative damage. Whereas in a non-polar membrane environment, nitrocarbonate causes reactions, for example, leading to nitration of proteins and oxidative damage. However, when NO reacts with oxygen in the absence of superoxide, N₂O₃.CO₂ is formed, which in normal physiological conditions when interacting with CO₂ is hydrolyzed to nitric and carbonic acids [25, 26].

Therefore, CO₂, preventing nitration reactions and oxidative damage has an antioxidant effect, which, for example, is confirmed by the normalization of the activity of superoxide dismutase (SOD). It is logical to assume that in the body hypercapnia (high CO₂ content in the blood) protects tissues from the destructive effects of toxic products of ischemia or hypoxia, which result in the formation of ROS.

In addition to the above mechanisms of antioxidant action of CO₂ in vivo one mechanism was proposed - stabilization with CO₂ of iron-transferrin complex, which also prevents the participation of iron ions in the initiation of free radical reactions [7]. Also, it has been proven that ROS such as H₂O₂, hydroxyl anion, and, mainly, superoxide found in the endothelium in ischemia and hypoxia, can be produced by modulation by mitochondria unrelated to nitric oxide synthetase, but with the participation of various oxidases: xanthine oxidase, COX, lipooxygenase, [27, 28, 29]. CO₂ blocking ROS, formed by the above mechanism, also contributes to the development of the antioxidant activity.

It is now known that increased levels of ROS are considered one of the main factors in the aging of organs, tissues, and the body as a whole [30, 31, 32]. On the other hand, physiological ROS production is required for signaling in normal cells because ROS serve as additional messengers involved in regulating the metabolism of mitogen-activated protein kinase, which acts as a pacemaker for cell growth, inflammation, apoptosis, and differentiation of cells. [5, 25]. The pathophysiological link between these physiological and pathological conditions is the presence of severe oxidative stress.

In another study of the relationship between oxidative stress and CO₂, it was found that CO₂ plays a protective role in the process of removing free radicals and suppressing the

expressed oxidative metabolism. Thus, it was found that asymmetric dimethylarginine (ADMA) inhibits the formation of NO and increases the level of free radicals in blood vessels, which leads to increased oxidative stress [33, 34, 35]. It is known that NO is a key vasodilator molecule that not only regulates vascular tone but also has antiplatelet, anti-inflammatory, and antioxidant properties. NO production is also closely linked to the activation of the endothelial nitric oxide synthetase (NOS) molecule, which is an indicator of vascular endothelial cell function: NOS promotes angiogenesis and suppresses myocardial fibrosis in cardiac dysfunction associated with high blood pressure [36].

As mentioned above, ADMA is an inhibitor of endogenous NO synthesis, and elevated concentrations of ADMA (a marker of oxidative stress) have been found in plasma in patients with classic cardiovascular diseases (CVD), as well as in the presence of other adverse risk factors: hypertension, diabetes mellitus, obesity [37, 38]. Therefore, ADMA is an informational natural factor for studying the relationship between the NO and CO₂ systems, especially under conditions of oxidative stress and inflammation, since ADMA is considered a mediator and marker of oxidative stress and inflammation. Not only ADMA can affect endothelial dysfunction but also cleaves electron transfer between NOS and L-arginine [39]. Whereas CO₂ inhalations enhance the activation of the NOS isoenzyme, and increasing this activity can lead to improved myocardial function[8]. The reliable prognostic value of CO₂ in the assessment of CVD risk was also confirmed by a systematic analysis of ADMA values in CVD patients. It is known that the decrease in ADMA activity is directly proportional to the severity of oxidative stress in CVD [33, 35, 37]. Other studies have shown that CO₂ can reduce the level of ADMA, and this also confirms that CO₂ is a natural physiological inhibitor of ROS generation [12].

Confirmation of the antioxidant action of CO₂ is also the result of the analysis of the content of serum d-ROM (an indicator of systemic oxidative stress) in myocardial infarction (MI). It is well known that oxidative stress is an important factor that negatively affects heart function [40]. Against the background of MI in systemic oxidative stress, the level of serum d-ROM is increased. It was found that the preliminary invasive administration of CO₂ leads to a significant decrease in the level of d-ROM [13]. Reduction of IM-induced content of d-ROM with pre-administration of CO₂ indicates that carboxytherapy can reduce both systemic and local oxidative stress, possibly by enhancing the compensatory effects of natural antioxidant systems, which in turn reduces oxidative and inflammatory processes in myocardium cells [22]. However, the exact mechanism of this action is not entirely clear.

Thus, based on the above, we can conclude that CO₂ paired with O₂ maintains the viability of our body. Violation of this balance leads to increased oxidative stress, the development of pathological conditions with the formation of ROS, which are the main trigger of aging, disrupting the subtle and complex biochemical intracellular processes of the body. Whereas CO₂ in physiological concentrations eliminates hypoxia, ischemia, reduces the rate of oxidative reactions, and thus exhibits antioxidant properties, contributing to the effect of "anti-aging". Therefore, prolonged hypocapnia and hypoxia can serve as a trigger for pathological processes in the body, in particular the suppression of natural antioxidant systems [41]. The accumulation of underoxidized metabolic products (ROS, etc.) in the tissues causes a painful reaction. Many studies have shown that the elimination of hypoxia with carboxytherapy, reduces the formation of these pathological products and promotes their removal from the body, thereby reducing pain [42].

Another aspect of the antioxidant effect of carboxytherapy application may be diabetes mellitus (DM) [41]. Currently, the cyclic process of LPO in the body is considered a universal pathological mechanism, which explains the main biochemical pathways of the toxic effects of hyperglycemia on the body. A significant breakthrough in understanding the pathological mechanisms of damage to β -cells of the pancreas in diabetes was the study of the biochemical significance of NO and cytokines that induce the expression of NO synthetase [44]. The latter, in turn, in β -cells promotes the formation of NO from L-arginine, which leads to the subsequent formation of free radical compounds and as a consequence to the destruction of β -cells [45]. Thus, in diabetes not only the formation of free radicals is activated, but also the activation of free radical oxidation processes in β -cells of the pancreas and other organs and tissues [41]

Therefore, to prevent or reduce the processes of free radical oxidation that cause damage in diabetes, it is justified not only to use drugs that can correct the development of hyperglycemia but also carboxytherapy that complements the treatment of diabetes, as one of the mechanisms of carboxytherapy in this pathology is its antioxidant action [41].

Thus, in the study of the intensity of the processes of LPO and the antioxidant activity of CO₂ by the method of induced biochemiluminescence it has been revealed that after "dry" carbon dioxide baths the antioxidant system is activated, as evidenced by a 21.2% decrease in plasma free radicals, malonic dialdehyde - by 11.9%, 6.5% increased activity of erythrocyte catalase, and there was a downward trend in diene conjugates noted [46].

Therefore, due to the antioxidant properties and participation in the maintenance of acid-base balance, carbon dioxide in natural (physiological) concentrations:

dilates narrowed small arteries and capillaries, while the reduction of carbon dioxide in the blood leads to their spasm and the opening of arteriovenous shunts, which impairs blood circulation in the tissues;

normalizes venous tone, as at insufficient tone of veins venous stagnation of blood develops, the outflow of blood from tissues is broken, their hypostasis amplifies, trophism and oxygenation worsens, toxic products of vital activity, including ROS, accumulate in tissues;

vasodilating and antioxidant action of CO₂ on vessels leads to expansion of coronary vessels, bradycardia, decrease in BP, improvement of trophism of tissues, in particular, a myocardium;

Under the action of CO₂ at the same time the need of heart muscle for O₂ is reduced by 18-22% and increases myocardial tolerance to exercise;

Blood CO₂ level reduction strengthens the binding of oxygen to hemoglobin that complicates the ingress of O₂ in tissues, while Russian scientist BF Verigo and Dane K. Bohr have independently proved that without CO₂ oxygen cannot be released from binding to hemoglobin, which leads to oxygen starvation of cells at high concentrations of O₂ in the blood;

due to the direct and reflex action of CO₂ on the vasomotor center of the medulla oblongata and the center of n. vagus redistribution of blood in an organism occurs, peripheral vessels dilate, the anaerobic energy exchange is mobilized and trophic processes improve;

Analysis of the above changes in the body under the action of CO₂ and states of biochemical markers (ADMA and d-ROM, ROS, NO, NOS) under oxidative stress indicate that CO₂ has antioxidant properties, and carboxytherapy is a pathogenetic therapy for diseases which pathogenesis includes oxidative stress.

Thus, it has been established that CO₂ is a universal inhibitor of the reactive oxygen

species generation by various human and animal cells. These data allow explaining the physiological and pathophysiological (medical) effects of CO₂ in the mechanism of carboxytherapy in a new way from the standpoint of the biochemical role of ROS.

References

1. Khat L, Leibaschoff GH. Clinical Prospective Study on the Use of Subcutaneous Carboxytherapy in the Treatment of Diabetic Foot Ulcer. *Surg Technol Int.* 2018 Jun 1; 32: 81-90. PMID: 29566422.
2. Park JH, Wee SY, Chang J, Hong S, Lee JH, Cho KW, Choi CY. Carboxytherapy-Induced Fat loss is Associated with VEGF-Mediated Vascularization. *Aesthetic Plast Surg.* 2018 Dec; 42 (6): 1681-1688. doi: 10.1007 / s00266-018-1222-y.
3. Carboxytherapy as one of the innovative directions in balneology / SM Drogovoz, ND Bunyatyan [and others] // Questions of balneology, physiotherapy, and remedial physical culture. 2018. - Vol. 95. - No. 5. - P. 72-76.
4. Zelenková H Carboxytherapy - a non-invasive method in aesthetic medicine and dermatology, and the combined usage of carboxytherapy and PRP in the periorbital area / *Glob Dermatol.*, 2017. Vol.4 (1): 1-5 doi: 10.15761 / YEAR.1000202.
5. The mechanism of action of carboxytherapy / SM Drogovoz [and others] // *Pharmacology and drug toxicology.* - 2016. - No. 6. (51). - P. 12-20.
6. Carboxytherapy: mechanisms, effects, applications: a handbook / Ed. Drogovoz SM. Kh.: "Title". 2019. 192 p.
7. The uniqueness of pharmacotherapeutic possibilities of carbon dioxide (carboxytherapy) / Drogovoz SM, et al. *Rational pharmacotherapy.* 2016. No. 1. Pp. 37-39.
8. Pagourelas ED, Zorou PG, Tsaligopoulos M, Athyros VG, Karagiannis A, Efthimiadis GK. Carbon dioxide balneotherapy and cardiovascular disease. *Int J Biometeorol.* 2011 Sep; 55 (5): 657-63. doi: 10.1007 / s00484-010-0380-7. Epub 2010 Oct 22. PMID: 20967468.
9. Zavyalova OR Application of carbon dioxide in medical rehabilitation Medical hydrology and rehabilitation. 2011. Pp. 72-83.

10. Modulating role of CO₂ in the action of reactive oxygen species / Kogan A. Kh., Grachev SV: GEOTAR - Media, 2006. - 224 p.
11. Pharmacological substantiation of carboxytherapy (CO₂ therapy) / Drogovoz SM et al. Pharmacology and drug toxicology. 2017. No. 1 (52). Pp. 73-78.
12. Carbon dioxide production during cardiopulmonary bypass: pathophysiology, measure and clinical relevance / M. Ranucci et al. Perfusion. 2017. Vol. 32. P. 4-12.
13. Percutaneous carbon dioxide therapy can reduce peripheral vascular resistance in hypertensive patients / Nemeth B, Kiss I, Aytay B, Peter I, Cresca Z et al. In Vivo. 2018. Vol. 32 (6). P.1555-1559.
14. Bunyatyan ND, Drogovoz SM, Shtroblya AL, Kononenko AV, Zelenkova H, Prokofyev AB, Sapovsky MM, Nikolaeva LL. Mekhanizm pul'moprotektomogo deĭstviia karboksiterapii [The mechanism of the pulmoprotective action of carboxytherapy]. Vopr Kurortol Fizioter Lech Fiz Kult. 2019;96(4):58-62. Russian. doi: 10.17116 / kurort20199604158 /
15. Mechanisms of carboxytherapy action with diseases of the nervous system / Zelenkova H. et al. J. Derma. 2018. Vol. XVIII. - No. 1-2. P. 66-70.
16. The role of carbon dioxide in the free-radical reactions of the body / Vesela A., William J. Physiol Res. 2002. V. 51 (4). P. 335-339.
17. Weidinger A., Kozlov AV Biological activities of Reactive Oxygen and Nitrogen Species: Oxidative Stress versus Signal Transduction. Biomolecules. 2015. No. 5. P. 472-484.
18. Bunyatyan ND, Drogovoz SM, Kononenko AV, Prokofiev AB. Karboksiterapiia - odno iz innovatsionnykh napravlenii v kurortologii [Carboxytherapy - an innovative trend in resort medicine]. Vopr Kurortol Fizioter Lech Fiz Kult. 2018; 95 (5): 72-76. Russian. doi: 10.17116 / kurort20189505172.
19. Zelenkova, H. Staget combined therapy of poor healing lower leg wounds due to chronic venous insufficiency / H. Zelenkova // J. Clin. Cell. Rev. Immunol. - 2016. - Vol. 7, No. 5. - P. 33.
20. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000 Jul;130(5):963-74. doi: 10.1038/sj.bjp.0703393. PMID: 10882379; PMCID: PMC1572156.
21. Lee LL, Khakoo AY, Chintalgattu V. Cardiac pericytes function as key vasoactive cells to regulate homeostasis and disease. FEBS Open Bio. 2021 Jan; 11 (1): 207-225. doi: 10.1002 / 2211-5463.13021. Epub 2020 Dec 14. PMID: 33135334; PMCID: PMC7780101.
22. Percutaneous carbon dioxide treatment has a protective effect in experimental myocardial infarction / Takehiro Yamaguchi, Takanori Yamazaki, Yasuhiro Nakamura. J. Pharmacol. Sci. 2015. Vol. 127 (4). P.474-480.
23. Levels from asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and the risk of coronary heart disease: a meta-analysis based on 4713 participants / Xuan S., Tien K. V, Li X. et al. Eur J Prev Cardiol. 2016. Vol. 23 (5). P. 502-510. doi: 10.1177 / 2047487315586094.
24. Oxidative stress and antioxidants for hypertension - an up-to-date overview / Sinha N., Double PC Tech Hypertens Rev. 2015. Vol. 11 (2). P. 132-142.
25. The role of nitric oxide in the processes of free radical oxidation / Solovieva AG et al. Bulletin of the Russian Military Medical Academy. 2016. No. 1 (53). Pp. 228-233.
26. Free radical oxidation of lipids and proteins - a unique process of vital activity of the organism / Lutsky MA et al. Successes of modern natural science. 2014. No. 12. Pp. 24-28.
27. Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018 Jan; 100: 1-19. doi: 10.1016 / j.vph.2017.05.005 Epub 2017 Jun 1. PMID: 28579545.
28. Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018 Feb; 40 (2): 215-224. doi: 10.1007 / s00281-017-0666-5. Epub 2017 Dec 5. PMID: 29209827; PMCID: PMC5809518.
29. The property of carbon dioxide to inhibit the generation of superoxide anion radical by cells and its biomedical value / Kogan A. Kh., Grachev SV, Eliseeva SV, Bolevich S. Questions of

- medicine and chemistry Experimental researches. 1996. No. 42 (3). Pp. 193-202.
30. Kudryavtseva AV, Krasnov GS, Dmitriev AA, Alekseev BY, Kardymon OL, Sadritdinova AF, Fedorova MS, Pokrovsky AV, Melnikova NV, Kaprin AD, Moskalev AA, Snezhkina AV. Mitochondrial dysfunction and oxidative stress in aging and cancer. *Oncotarget*. 2016 Jul 19;7(29):44879-44905. doi: 10.18632/oncotarget.9821. PMID: 27270647; PMCID: PMC5216692.
31. Gomes MJ, Martinez PF, Pagan LU, Damatto RL, Cezar MDM, Lima ARR, Okoshi K, Okoshi MP. Skeletal muscle aging: influence of oxidative stress and physical exercise. *Oncotarget*. 2017 Mar 21;8(12):20428-20440. doi: 10.18632/oncotarget.14670. PMID: 28099900; PMCID: PMC5386774.
32. Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. *Free Radic Biol Med*. 2015 Nov;88(Pt B):314-336. doi: 10.1016/j.freeradbiomed.2015.05.036. Epub 2015 Jun 9. PMID: 26066302; PMCID: PMC4628850.
33. Inan B, Ates I, Ozkayar N, Kundi H, Topcuoglu C, Dede F, Sennaroglu E. Are increased oxidative stress and asymmetric dimethylarginine levels associated with masked hypertension? *Clin Exp Hypertens*. 2016; 38 (3): 294-8. doi: 10.3109 / 10641963.2015.1089883. Epub 2016 Mar 28. PMID: 27018581.
34. Rochette L, Lorin J, Zeller M, Guillard JC, Lorgis L, Cottin Y, Vergely C. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? *Pharmacol Ther*. 2013 Dec; 140 (3): 239-57. doi: 10.1016 / j.pharmthera.2013.07.004. Epub 2013 Jul 13. PMID: 23859953.
35. Plicner D, Mazur P, Sadowski J, Undas A. Asymmetric dimethylarginine and oxidative stress following coronary artery bypass grafting: associations with postoperative outcome. *Eur J Cardiothorac Surg*. 2014 May;45(5):e136-41. doi: 10.1093/ejcts/ezt646. Epub 2014 Feb 11. PMID: 24523493.
36. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. *Curr Vasc Pharmacol*. 2012 Jan;10(1):4-18. doi: 10.2174/157016112798829760. PMID: 22112350.
37. Liu X, Xu X, Shang R, Chen Y. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. *Nitric Oxide*. 2018 Aug 1; 78: 113-120. doi: 10.1016 / j.niox.2018.06.004 Epub 2018 Jun 19. PMID: 29928990; PMCID: PMC6301111.
38. Alpoim PN, Sousa LP, Mota AP, Rios DR, Dusse LM. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease. *Clin Chim Acta*. 2015 Feb 2;440:36-9. doi: 10.1016/j.cca.2014.11.002. Epub 2014 Nov 7. PMID: 25444745.
39. Siervo M, Corander M, Stranges S, Bluck L. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). *Nutr Metab Cardiovasc Dis*. 2011 Jan; 21 (1): 1-10. doi: 10.1016 / j.numecd.2010.10.003. Epub 2010 Dec 14. PMID: 21159496.
40. Sugiura T, Dohi Y, Takase H, Fujii S, Seo Y, Ohte N. Relationship of pulmonary function with myocardial microdamage and oxidative stress in the Japanese population without a history of cardiopulmonary disease. *Medicine (Baltimore)*. 2020 Aug 28;99(35):e21945. doi: 10.1097/MD.0000000000021945. PMID: 32871941; PMCID: PMC7458258.
41. The effect of hypercapnia on resting and stimulus induced MEG signals / Hall E. L. et al. *Neuroimage*. 2011. Vol.58, No. 4. P. 1034-1043.
42. Carboxytherapy - an alternative to traditional pharmacotherapy / SM Drogovoz [et al.] // *Clinical Pharmacology*. - 2016. - Vol. 20, No. 1. - P. 12-17.
43. Carboxytherapy as an alternative off-label method for diabetes mellitus treatment: a review / Drogovoz SM, Kalko KO, Hailat IA, Ivantsyk LB, Kireyev IV *Pharmacologyonline*. Vol. 3. 2021. P. 447-455. https://pharmacologyonline.silae.it/files/archives/2021/vol1/PhOL_2021_1_A051_Drogovoz.pdf
44. Nitric oxide: properties, biological role, mechanisms of action / Kuznetsova VL, Solovyova AG *Modern problems of science and education*. 2015. No. 4. Pp. 24-29.
45. Arterial hypertension with inhibition of vascular endothelial growth factor: focus on nitric oxide, endothelin-1 and oxidative stress // Lankhorst S.,

- Kappers M. H, Van Esch JH et al. Antioxidant redox signal. 2014. Vol 20 (1). P.135-45.
46. Zbroja H, Kowalski M, Lubkowska A. The Effect of Dry Carbon Dioxide Bathing on Peripheral Blood Circulation Measured by Thermal Imaging among Patients with Risk Factors of PAD. Int J Environ Res Public Health. 2021 Feb 4; 18 (4): 1490. doi: 10.3390/ijerph18041490